Indicators for Monitoring and Evaluation of Community-Based Injectable Contraception: Multisourced Process and New Global Guidance

Jill M Peterson,John Stanback,Kirsten Krueger

doi:10.9745/ghsp-d-19-00133

Jill M Peterson, John Stanback + Show 1 more

Open Access

https://doi.org/10.9745/ghsp-d-19-00133

Copy DOI

Abstract

For many women, convenient access to family planning in their communities provides the impetus they need to start and maintain use of a family planning method. The benefits of family planning task shifting, which allows community health workers (CHWs) to provide methods such as oral contraceptive pills and injectables within communities, were publicly recognized by the World Health Organization (WHO) in 2009. WHO's 2012 global guidelines on task sharing recommended CHW provision of injectable contraception, accompanied by targeted monitoring and evaluation (M&E); however, the term "targeted" was not defined. To fill this gap, we undertook a literature review, technical consultation, and case studies in Malawi, Senegal, and Uganda to inform our development of a list of M&E indicators, supporting guidance, and job aids to help strengthen community-based access to injectable contraception programs and their ability to follow WHO recommendations. We identified 4 essential indicators: there are enough CHWs certified to provide injectables to meet project goals, CHWs are being appropriately supervised to ensure client safety, the stock of injectables is reliable and can meet project goals, and clients are receiving injections.

Highlights

Global Health: Science and Practice 2019 | Volume 7 | Number 3 the World Health Organization (WHO) included it in their written guidance in 2012.8,9 The document on optimizing health workers’ roles focused on task sharing for maternal and newborn health and recommended that community health workers (CHWs) provision of injectable contraception be accompanied by “targeted” monitoring and evaluation (M&E).[9]
To assist countries in following this WHO recommendation, we developed written guidance on M&E of CBA2I, including recommended M&E indicators
We developed the M&E guidance and indicators, using a systematic, 3-stage process that included a literature review, a technical consultation, and case studies

Summary

Introduction

Global Health: Science and Practice 2019 | Volume 7 | Number 3 the World Health Organization (WHO) included it in their written guidance in 2012.8,9 The document on optimizing health workers’ roles focused on task sharing for maternal and newborn health and recommended that CHW provision of injectable contraception be accompanied by “targeted” monitoring and evaluation (M&E).[9] the guidelines did not define what this particular type of M&E should entail. More than a dozen countries have implemented CBA2I programs, including some of those with the poorest access to contraception, and approximately 10 others are exploring the possibility or have discussions or pilot programs underway. To assist countries in following this WHO recommendation, we developed written guidance on M&E of CBA2I, including recommended M&E indicators. This article outlines the process we used to develop the guidance and indicators

Results

Discussion

Conclusion